Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bedford Laboratories, a division of Ben Venue Laboratories, offering a range of multisource injectables across multiple therapeutic classes, has added Dactinomycin for injection USP 500mcg (0.5mg) to its line of generic oncology products.
Subscribe to our email newsletter
Dactinomycin has received approval from the FDA earlier this year. It is an equivalent of Lundbeck’s Cosmegen. Each single dose vial contains 0.5mg (500mcg) of dactinomycin and 20mg of mannitol and is individually boxed.
Dactinomycin, as part of a combination chemotherapy and/or multi-modality treatment regimen, is indicated for the treatment of Wilms’ tumor, childhood rhabdomyosarcoma, Ewing’s sarcoma and metastatic nonseminomatous testicular cancer.
Dactinomycin is indicated as a single agent, or as part of a combination chemotherapy regimen, for the treatment of gestational trophoblastic neoplasia.
Additionally, Dactinomycin, as a component of regional perfusion, is indicated for the palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies.
Dactinomycin is known to interfere with the growth of cancer cells and slow their growth and spread in the body.